Technical Analysis for AVBP - ArriVent BioPharma, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 20 DMA | Bullish | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% | |
| Gapped Down | Weakness | 0.00% | |
| 20 DMA Resistance | Bearish | 1.03% | |
| MACD Bullish Signal Line Cross | Bullish | 2.14% | |
| Outside Day | Range Expansion | 2.14% | |
| Gapped Up | Strength | 2.14% | |
| 180 Bearish Setup | Bearish Swing Setup | 8.10% | |
| Slingshot Bearish | Bearish Swing Setup | 8.10% | |
| Calm After Storm | Range Contraction | 8.10% |
| Alert | Time |
|---|---|
| Up 5% | about 18 hours ago |
| Rose Above Previous Day's High | about 19 hours ago |
| Up 3% | about 19 hours ago |
| Possible Inside Day | about 19 hours ago |
| 60 Minute Opening Range Breakout | about 21 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: Unknown
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Solid Tumors Cancer Treatment Non Small Cell Lung Cancer Antineoplastic Drugs Lung Cancer Orphan Drug Protein Kinase Inhibitor Tyrosine Kinase Cancer Therapies NSCLC Bemcentinib
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Solid Tumors Cancer Treatment Non Small Cell Lung Cancer Antineoplastic Drugs Lung Cancer Orphan Drug Protein Kinase Inhibitor Tyrosine Kinase Cancer Therapies NSCLC Bemcentinib
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 25.95 |
| 52 Week Low | 14.35 |
| Average Volume | 196,616 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 18.16 |
| 20-Day Moving Average | 16.59 |
| 10-Day Moving Average | 15.85 |
| Average True Range | 1.19 |
| RSI (14) | 47.92 |
| ADX | 21.33 |
| +DI | 15.11 |
| -DI | 17.61 |
| Chandelier Exit (Long, 3 ATRs) | 15.38 |
| Chandelier Exit (Short, 3 ATRs) | 17.91 |
| Upper Bollinger Bands | 18.47 |
| Lower Bollinger Band | 14.71 |
| Percent B (%b) | 0.53 |
| BandWidth | 22.68 |
| MACD Line | -0.63 |
| MACD Signal Line | -0.78 |
| MACD Histogram | 0.1509 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 19.14 | ||||
| Resistance 3 (R3) | 19.11 | 18.27 | 18.73 | ||
| Resistance 2 (R2) | 18.27 | 17.64 | 18.28 | 18.60 | |
| Resistance 1 (R1) | 17.48 | 17.26 | 17.87 | 17.51 | 18.46 |
| Pivot Point | 16.63 | 16.63 | 16.83 | 16.65 | 16.63 |
| Support 1 (S1) | 15.84 | 16.01 | 16.24 | 15.87 | 14.92 |
| Support 2 (S2) | 15.00 | 15.62 | 15.01 | 14.78 | |
| Support 3 (S3) | 14.21 | 15.00 | 14.65 | ||
| Support 4 (S4) | 14.24 |
